BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15112475)

  • 1. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
    Jabłońska E; Chłosta M; Pawlega J
    Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ
    Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer.
    Rose PG
    Semin Oncol Nurs; 2003 Nov; 19(4 Suppl 2):25-35. PubMed ID: 14702918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
    Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 9. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
    Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
    Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H
    Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Pérez-López ME; Curiel T; Gómez JG; Jorge M
    Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin in refractory epithelial ovarian cancer.
    Kavanagh JJ; Nicaise C
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):45-8. PubMed ID: 2655098
    [No Abstract]   [Full Text] [Related]  

  • 19. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
    Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
    Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.